Women with hormone receptor-positive breast cancers are commonly treated post-surgery for five years with drugs that interfere with the hormone-tumor interaction. But sometimes the cancer reoccurs, and the initial tumor and lymph node status seems to be important in determining who would be at the greatest risk of recurrence.
